Risperdal Lawsuit Update 2020: A Comprehensive Overview
The year 2020 brought significant developments in the ongoing Risperdal lawsuits, with Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, facing numerous claims alleging that the antipsychotic drug Risperdal caused serious side effects, particularly gynecomastia (male breast growth) in young men and boys.
Understanding Risperdal and its Side Effects
Risperdal, a atypical antipsychotic medication, was approved by the FDA in 1993 for the treatment of schizophrenia. In 2006, it was also approved for treating bipolar disorder in children and adolescents. However, lawsuits allege that Johnson & Johnson and Janssen failed to adequately warn patients and healthcare providers about the potential risks associated with Risperdal, including gynecomastia, weight gain, and movement disorders.
Key Developments in Risperdal Lawsuits in 2020
- Philly Mass Tort Program: In January 2020, the Philadelphia Court of Common Pleas consolidated over 600 Risperdal lawsuits into a mass tort program, streamlining the pretrial process.
- Bellwether Trials: Throughout 2020, several bellwether trials were scheduled and concluded, providing insights into how juries might rule in similar cases. These trials involved plaintiffs who alleged that Risperdal caused gynecomastia.
- Settlements and Verdicts: While many cases settled confidentially, some notable verdicts were reached in 2020. In one case, a jury awarded a plaintiff $8 billion in punitive damages, although this verdict was later reduced on appeal.
Risperdal and Gynecomastia: The Core Allegation
Gynecomastia, the growth of breast tissue in males, is one of the most common and well-documented side effects of Risperdal. Lawsuits allege that Johnson & Johnson and Janssen were aware of this risk but failed to provide adequate warnings. In some cases, plaintiffs allege that they were prescribed Risperdal off-label for conditions not approved by the FDA, such as autism spectrum disorders and attention deficit hyperactivity disorder (ADHD).
Regulatory Actions and Criticism
In 2013, Johnson & Johnson agreed to pay $2.2 billion to resolve criminal and civil investigations into its marketing practices for Risperdal and other drugs. The company was accused of promoting Risperdal for unapproved uses and failing to disclose known side effects. Despite this, lawsuits continue to allege that the company's marketing practices were deceptive and put patients at risk.
FDA Warnings
The FDA has issued several warnings regarding Risperdal and its potential side effects. In 2006, the agency added a black box warning to the drug's label, the most serious type of warning, to highlight the risk of gynecomastia. In 2011, the FDA required Janssen to add a warning about the risk of diabetes and related complications.
What's Next in the Risperdal Litigation?
As of now, thousands of Risperdal lawsuits are still pending in courts across the country. In 2021, many of these cases are expected to move forward, with more bellwether trials and potential settlements. As the litigation continues, it remains crucial for patients and healthcare providers to be aware of the potential risks associated with Risperdal and other antipsychotic medications.
